Live Analyst Rating Changes 24957 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Ryan Zimmerman
BTIG

Ryan Zimmerman

Wall Street Analyst
★★☆☆☆
#2211
on 13Foresight · ranked by our own returns
55%
Success Rate
+1.6%
Average Return
52 of 94 calls profitable · -4.0% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 55% of Ryan Zimmerman's ratings turned a profit when each position was held for 1 year — averaging +1.6% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

155 Buy 78 Hold 2 Sell
Ryan's Stock Coverage 38 ratings · 2026-08-16
Company Date Position Consensus Price Target 1-Yr Return vs S&P 500
TCMD
Tactile Systems Technology
Aug 11, 2026 BUY Strong Buy
+68.7% avg upside
8 analysts
$39.00
61.10% Upside
-1.3% ·
GMED
Globus Medical
Aug 07, 2026 HOLD Strong Buy
+7.3% avg upside
24 analysts
+4.3% ·
SI
Shoulder Innovations, Inc.
Aug 07, 2026 BUY Strong Buy
+13.8% avg upside
5 analysts
$26.00
25.41% Upside
-5.5% ·
ORGO
Organogenesis Holdings
Aug 07, 2026 HOLD Strong Buy
+548.0% avg upside
8 analysts
-3.8% ·
RCEL
Avita Medical
Aug 07, 2026 BUY Strong Buy
+36.1% avg upside
11 analysts
$7.00
10.87% Downside
+1.0% ·
SOLV
Solventum Corporation
Aug 06, 2026 BUY Buy
+3.1% avg upside
16 analysts
$95.00
7.26% Upside
+6.8% ·
CARL
Carlsmed, Inc.
Aug 06, 2026 BUY Strong Buy
+31.3% avg upside
6 analysts
$23.00
60.60% Upside
+4.5% ·
RXST
RxSight
Aug 06, 2026 HOLD Hold
+29.0% avg upside
13 analysts
+13.3% ·
PRCT
PROCEPT BioRobotics
Aug 05, 2026 HOLD Buy
+47.4% avg upside
17 analysts
+11.9% ·
KIDS
OrthoPediatrics
Aug 05, 2026 BUY Strong Buy
+26.2% avg upside
10 analysts
$24.00
3.19% Downside
+11.2% ·
SYK
Stryker
Jul 31, 2026 BUY Strong Buy
+8.8% avg upside
37 analysts
$358.00
5.60% Upside
+4.7% ·
GKOS
Glaukos
Jul 30, 2026 BUY Strong Buy
-8.6% avg upside
21 analysts
$193.00
4.61% Upside
+9.5% ·
GEHC
GE Healthcare Technologies Inc
Jul 29, 2026 BUY Strong Buy
+11.5% avg upside
22 analysts
$79.00
7.16% Upside
+2.5% ·
HUMA
Humacyte
Jul 28, 2026 BUY Strong Buy
+1003.7% avg upside
11 analysts
$2.00
230.73% Upside
-4.1% ·
ZBH
Zimmer Biomet Holdings
Jul 23, 2026 HOLD Buy
+13.5% avg upside
38 analysts
+12.3% ·
ISRG
Intuitive Surgical
Jul 17, 2026 BUY Strong Buy
+21.9% avg upside
36 analysts
$469.00
18.79% Upside
+14.2% ·
STAA
Staar Surgical
Jul 16, 2026 HOLD Hold
+30.2% avg upside
16 analysts
-9.7% ·
MDT
Medtronic
Jul 13, 2026 BUY Buy
+5.6% avg upside
38 analysts
$91.00
0.28% Downside
+9.2% ·
LNSR
LENSAR
Jul 10, 2026 BUY Strong Buy
+58.6% avg upside
4 analysts
$7.00
14.72% Downside
+36.4% ·
PEN
Penumbra
Jul 10, 2026 HOLD Buy
+1.0% avg upside
23 analysts
+2.8% ·
ENOV
Enovis
Jul 06, 2026 BUY Strong Buy
+156.9% avg upside
39 analysts
$39.00
49.57% Upside
+0.6% ·
MOBI
Mobia Medical, Inc.
Jun 22, 2026 BUY Strong Buy
+76.4% avg upside
4 analysts
$19.00
61.52% Upside
-15.2% ·
IART
Integra Lifesciences
Jun 22, 2026 HOLD Buy
+136.6% avg upside
21 analysts
+3.6% ·
MDAI
Spectral AI
May 26, 2026 BUY Strong Buy
+160.4% avg upside
4 analysts
$4.00
138.05% Upside
-29.1% ·
VCEL
Vericel
Apr 05, 2026 HOLD Strong Buy
+7.2% avg upside
16 analysts
+29.7% ·
XTNT
Xtant Medical Holdings
Mar 31, 2026 BUY Strong Buy
+1790.7% avg upside
9 analysts
$1.00
227.87% Upside
-44.6% ·
CH:ALC
Alcon
Mar 23, 2026 BUY Strong Buy
+17.8% avg upside
35 analysts
$74.86
23.36% Upside
+1.8% ·
RBOT
Vicarious Surgical
Nov 13, 2025 HOLD Buy
+20733.4% avg upside
6 analysts
-98.3% ·
TMCI
Treace Medical Concepts
Nov 07, 2025 HOLD Hold
+24.5% avg upside
8 analysts
+7.3% ·
OFIX
Orthofix Medical
Feb 25, 2025 HOLD Buy
+172.9% avg upside
15 analysts
-25.5% ·
IRTC
Irhythm Technologies
Oct 16, 2023 BUY Strong Buy
+32.1% avg upside
20 analysts
$132.00
4.31% Upside
-26.8% ·
AXGN
AxoGen
Aug 18, 2023 HOLD Strong Buy
-28.0% avg upside
21 analysts
+104.0% ·
PODD
Insulet
Apr 17, 2023 BUY Strong Buy
+51.6% avg upside
32 analysts
$350.00
144.17% Upside
-48.2% ·
GE
GE Aerospace
Apr 10, 2023 HOLD Strong Buy
-36.5% avg upside
49 analysts
+108.4% ·
MDWD
Mediwound
Oct 14, 2022 HOLD Strong Buy
+57.8% avg upside
13 analysts
-3.7% ·
ECOR
Electrocore
Jul 30, 2021 HOLD Strong Buy
+512.8% avg upside
10 analysts
-44.6% ·
ABT
Abbott Laboratories
Aug 27, 2020 HOLD Strong Buy
+4.3% avg upside
36 analysts
+13.6% ·
OCGN
Ocugen
Dec 24, 2018 HOLD Strong Buy
+585.2% avg upside
17 analysts
-95.0% ·
🔒 33 more ratings — with price targets, crowd consensus and our measured returns.
Free account unlocks every analyst's full coverage table.
Ryan Zimmerman — Frequently Asked Questions
How accurate are Ryan Zimmerman's stock ratings?
Based on the calls 13Foresight could measure, about 55% of Ryan's ratings were profitable over a one-year hold, with an average return of +1.6% per rating, or -4.0% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Ryan ranked on 13Foresight?
Ryan Zimmerman is currently ranked #2211 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Ryan cover?
Ryan most recently has ratings on TCMD, GMED, SI, ORGO, RCEL, SOLV, CARL, RXST, PRCT, KIDS, SYK, GKOS and 26 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.